Market revenue in 2023 | USD 8.9 million |
Market revenue in 2030 | USD 13.9 million |
Growth rate | 6.6% (CAGR from 2023 to 2030) |
Largest segment | Attenuated vaccine |
Fastest growing segment | DNA Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines |
Key market players worldwide | Lonza Group Ltd, FUJIFILM Holdings Corp, Merck KGaA, Catalent Inc, Icon PLC, Syngene, Curia, Ajinomoto Co Inc, IDT Biologika |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.
Attenuated vaccine was the largest segment with a revenue share of 30.34% in 2023. Horizon Databook has segmented the UAE vaccine contract manufacturing market based on attenuated vaccine, inactivated vaccine, subunit vaccines, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The UAE has the world's most advanced medical technologies with government-funded comprehensive health services. In 2021, R&D expenditure share from the GDP was 1.50%. The availability of a large pool of researchers is attracting many CDMOs in the country. The clinical research sector in the UAE is performing well, with many pharmaceutical companies investing in studies.
Many global CROs outside the Gulf region are entering the UAE market and collaborating with preexisting local outsourcing organizations with the first-mover advantage. The regulatory environment in the UAE is flexible with respect to its acceptance of studies conducted abroad as long as data is appropriately validated.
The country also has fast-track approval of clinical trials with ICH-GCP guidelines, making the existing data reliable for sponsors who outsource the clinical research work, as stringent regulators such as the U.S. FDA continuously monitor data.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE vaccine contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into UAE vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account